China Biologic Products (NASDAQ:CBPO) Receiving Somewhat Positive Press Coverage, Report Finds

News headlines about China Biologic Products (NASDAQ:CBPO) have trended somewhat positive on Saturday, according to Accern Sentiment. Accern rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. China Biologic Products earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.0147846014701 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the headlines that may have impacted Accern’s scoring:

China Biologic Products (CBPO) traded up 0.37% during trading on Friday, reaching $91.51. The company had a trading volume of 206,663 shares. The firm has a 50-day moving average price of $102.40 and a 200 day moving average price of $107.46. China Biologic Products has a 12-month low of $90.32 and a 12-month high of $126.47. The stock has a market cap of $2.49 billion, a P/E ratio of 23.82 and a beta of 1.70.

China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.05. The business had revenue of $89.28 million for the quarter, compared to analysts’ expectations of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.26 earnings per share. Equities research analysts predict that China Biologic Products will post $4.96 EPS for the current fiscal year.

Several analysts have recently weighed in on the company. Jefferies Group LLC restated a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. Zacks Investment Research downgraded China Biologic Products from a “hold” rating to a “sell” rating in a research note on Friday, May 5th. Goldman Sachs Group, Inc. (The) assumed coverage on China Biologic Products in a research note on Tuesday, May 30th. They set a “neutral” rating for the company. Finally, BidaskClub downgraded China Biologic Products from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $132.00.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thestockobserver.com/2017/08/12/china-biologic-products-nasdaqcbpo-receiving-somewhat-positive-press-coverage-report-finds.html.

About China Biologic Products

Insider Buying and Selling by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply